Correlation Between Cell Source and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both Cell Source and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cell Source and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cell Source and Scopus Biopharma, you can compare the effects of market volatilities on Cell Source and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cell Source with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cell Source and Scopus Biopharma.
Diversification Opportunities for Cell Source and Scopus Biopharma
-0.53 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Cell and Scopus is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Cell Source and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Cell Source is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cell Source are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Cell Source i.e., Cell Source and Scopus Biopharma go up and down completely randomly.
Pair Corralation between Cell Source and Scopus Biopharma
If you would invest 44.00 in Cell Source on September 2, 2024 and sell it today you would earn a total of 16.00 from holding Cell Source or generate 36.36% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 1.56% |
Values | Daily Returns |
Cell Source vs. Scopus Biopharma
Performance |
Timeline |
Cell Source |
Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Cell Source and Scopus Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Cell Source and Scopus Biopharma
The main advantage of trading using opposite Cell Source and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cell Source position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.Cell Source vs. Pasithea Therapeutics Corp | Cell Source vs. Nutriband Warrant | Cell Source vs. MediciNova | Cell Source vs. Eliem Therapeutics |
Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |